Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial
Yanhang Gao(Jilin University), Junqi Niu(Jilin University), Jidong Jia(National Clinical Research Center for Digestive Diseases), Wen Chen(Fujian Medical University), Qingjing Zhu(Huazhong University of Science and Technology), Daidi Wang, Jinyu Xia(Sun Yat-sen University), Xiuhong Wen, Zhenjing Jin(Second Affiliated Hospital of Jilin University), Dengke Zhang(Wenzhou Medical University), Hesong Cui(Yanbian University Hospital), Tao Han(Tianjin Medical University), Yanhua Ding, Liang Chen(Qingdao Agricultural University), Peng Wang(Guangdong Medical College), Yongfeng Yang(Capital Medical University), Guangming Li(The Sixth People's Hospital of Zhengzhou), Weidong Liu(National University of Defense Technology), Chunmei Liu(Zunyi Medical University), Xinwen Song(First Affiliated Hospital of Xinxiang Medical University), Xuebing Yan(Nanjing Medical University), Xueyuan Jin(302 Military Hospital of China), Huanyu Gong(Central South University), Qing Mao(Johns Hopkins University), Yanzhong Peng(Peking University Shenzhen Hospital), Fei Kong(Shanghai Jiao Tong University), Zong Zhang(Jinan Infectious Disease Hospital), Mao Mu(Guiyang Medical University), Xiaolu Wu(First Affiliated Hospital of Xiamen University), Caiyan Zhao(Hebei Medical University), Weili Jin, Lvfeng Yao, Qianguo Mao(Army Medical University), Jia Shang(European Foundation for the Study of Chronic Liver Failure)
Cited by 15
Related Papers
Protection against persistence of hepatitis C
|The Lancet|2002|439
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Cellular immune selection with hepatitis C virus persistence in humans
|The Journal of Experimental Medicine|2005|304
The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways
|Nature Communications|2017|250